GH administration and discontinuation in healthy elderly men: effects on body composition, GH‐related serum markers, resting heart rate and resting oxygen uptake
- 1 July 2001
- journal article
- clinical trial
- Published by Wiley in Clinical Endocrinology
- Vol. 55 (1), 77-86
- https://doi.org/10.1046/j.1365-2265.2001.01344.x
Abstract
GH administration results in increased lean body mass (LBM), decreased fat mass (FM) and increased energy expenditure (EE). GH therapy may therefore have potential benefits, especially in the elderly, who are known to have decreased function of the GH/IGF-I axis. Several studies have focused on effects of GH administration in the elderly in the last decade. However, very limited information is available regarding changes in body composition and EE upon GH discontinuation in the elderly. The present study therefore investigated the effects of 12 weeks of GH administration and subsequent discontinuation on body composition, resting oxygen uptake (VO2), resting heart rate (HR) and GH related serum markers in healthy elderly men. Sixteen healthy men [age 74 +/- 1 years (mean +/- SEM), height 174.2 +/- 1.6 cm, body weight 80.7 +/- 2.6 kg, body fat 27.5 +/- 1.1%] completed the study protocol. Recombinant human GH (1.80 +/- 0.24 IU/day) was administered for 12 weeks in a single-blinded, placebo-controlled design. Body composition (dual energy X-ray absorptiometry), resting VO2 (indirect calorimetry), resting HR (telemetry) and serum IGF-I, IGF-II, IGFBP-3 and acid labile subunit (ALS) were measured at baseline, after 12 weeks of GH administration and, additionally in the GH group, 1, 2, 3, 4, 5 and 9 days after GH discontinuation. Body weight was unchanged from baseline to 12 weeks in both groups. However, GH administration caused a decrease in FM (3.4 +/- 1.0 kg, P < 0.012), paralleled by a similar increase in LBM (3.2 +/- 0.4 kg, P < 0.0002). Resting VO2 and resting HR increased by 31 +/- 3.6% and 7.3 +/- 1.9 per minute, respectively, in the GH-group, where significant increases in serum IGF-I, IGFBP-3 and ALS also were noted. None of the above parameters changed in the placebo group. Within 2-3 days after GH discontinuation, the GH related serum markers and resting HR returned to baseline levels, whereas resting VO2 remained elevated even 9 days after GH discontinuation. In addition, GH discontinuation caused a significant decrease in body weight (1.86 +/- 0.35 kg), derived exclusively from a decrease in LBM (1.63 +/- 0.43 kg), while the decreased FM was maintained (12 weeks: 17.93 +/- 1.65 kg, +9 days: 17.74 +/- 1.62 kg). The increases in serum IGF-I, IGFBP-3, ALS and resting heart rate induced by 12 weeks of GH administration in elderly men returned to baseline levels within 2-3 days after GH discontinuation. However, resting VO2 remained elevated for a longer period. GH administration reduced fat mass but maintained body weight by increasing lean body mass. In contrast, 9 days of GH discontinuation reduced body weight exclusively by reducing lean body mass.Keywords
This publication has 46 references indexed in Scilit:
- Regulation of uncoupling protein (UCP) 2 and 3 in adipose and muscle tissue by fasting and growth hormone treatment in obese humansInternational Journal of Obesity, 2000
- Regulation of Uncoupling Protein-2 and -3 by Growth Hormone in Skeletal Muscle and Adipose Tissue in Growth Hormone-Deficient AdultsJournal of Clinical Endocrinology & Metabolism, 1999
- The Acid-Labile Subunit of Human Ternary Insulin-Like Growth Factor Binding Protein Complex in Serum: Hepatosplanchnic Release, Diurnal Variation, Circulating Concentrations in Healthy Subjects, and Diagnostic Use in Patients with Growth Hormone DeficiencyJournal of Clinical Endocrinology & Metabolism, 1998
- Growth Hormone Treatment of Abdominally Obese Men Reduces Abdominal Fat Mass, Improves Glucose and Lipoprotein Metabolism, and Reduces Diastolic Blood PressureJournal of Clinical Endocrinology & Metabolism, 1997
- Calorigenic effects of growth hormone: the role of thyroid hormonesJournal of Clinical Endocrinology & Metabolism, 1996
- Growth hormone administration stimulates energy expenditure and extrathyroidal conversion of thyroxine to triiodothyronine in a dose‐dependent manner and suppresses circadian thyrotrophin levels: studies in GH‐deficient adultsClinical Endocrinology, 1994
- Growth hormone dose regimens in adult GH deficiency: effects on biochemical growth markers and metabolic parametersClinical Endocrinology, 1993
- Human growth hormone and human agingEndocrine Reviews, 1993
- Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomyJournal of Clinical Endocrinology & Metabolism, 1992
- The Effects of Treatment with Recombinant Human Growth Hormone on Body Composition and Metabolism in Adults with Growth Hormone DeficiencyNew England Journal of Medicine, 1989